Quarterly report pursuant to Section 13 or 15(d)

Liquidity and Financial Condition (Details Narrative)

v3.21.2
Liquidity and Financial Condition (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 25, 2021
Dec. 31, 2020
Entity Listings [Line Items]                
[custom:ReliefFunds]         $ 12,400,000      
Revenue recognized   $ 2,500,000   $ 7,500,000 12,400,000      
Working capital $ 57,500,000       57,500,000      
Accumulated deficit 1,012,970,661       1,012,970,661     $ 868,536,506
Loss from continuing operations (2,600,000)     $ (3,200,000) (7,900,000) $ (7,100,000)    
Cash used in operating activities         3,732,497 $ 9,123,430    
Advanced Molecular Services Group and Health Technology Solutions, Inc [Member] | Visual MED [Member]                
Entity Listings [Line Items]                
Disposal Group, Including Discontinued Operation, Liabilities             $ 2,200,000  
Advanced Molecular Services Group and Health Technology Solutions, Inc [Member] | Visual MED [Member] | Series B Preferred Stock [Member]                
Entity Listings [Line Items]                
Disposal Group, Including Discontinued Operation, Consideration             $ 8,500,000  
Public Health and Social Services Emergency Fund [Member]                
Entity Listings [Line Items]                
[custom:ReliefFunds]         100,000,000,000      
Public Health and Social Services Emergency Fund [Member] | Share-based Payment Arrangement, Tranche One [Member]                
Entity Listings [Line Items]                
[custom:ReliefFunds]         $ 30,000,000,000      
Provider Relief Funds [Member]                
Entity Listings [Line Items]                
Revenue recognized $ 1,900,000   $ 500,000